United States Atopic Dermatitis Market Insight
Published: 10 June 2026 | Report Format: Electronic (PDF)
The United States Atopic Dermatitis Market is projected to grow at a CAGR of around 8.1%, driven by the rising prevalence of atopic dermatitis, increasing adoption of biologic and targeted therapies, expanding awareness regarding chronic skin disease management, and continuous advancements in immunology-based treatment approaches.
United States Atopic Dermatitis Market Forecasts to 2035
- The United States Atopic Dermatitis Market Size Was Estimated at USD 9.84 Billion in 2025.
- The Market Size is Expected to Grow at a CAGR of around 8.1% from 2025 to 2035.
- The United States Atopic Dermatitis Market Size is Expected to Reach around USD 21.42 Billion by 2035.
Notable Insights for the United States Atopic Dermatitis Market
- Segmentation Based on Drug Class, the Biologics, Topical Corticosteroids, and JAK Inhibitors segments held a dominant position in the United States Atopic Dermatitis Market in 2025 with nearly 76% share, supported by superior efficacy and increasing adoption in moderate-to-severe disease treatment.
- Segmentation Based on Distribution Channel, Retail Pharmacies and Specialty Pharmacies collectively accounted for approximately 73% share in 2025, driven by strong prescription volumes, reimbursement support, and growing access to advanced dermatology therapies.
- The market is led by Sanofi, Regeneron Pharmaceuticals, and AbbVie; Sanofi reported approximately USD 53.44 billion revenue in FY2025, strengthening its leadership position in immunology, biologics development, and dermatology-focused therapeutic innovation.
- AbbVie generated approximately USD 58.05 billion revenue in FY2025, while Regeneron Pharmaceuticals reported nearly USD 15.10 billion revenue, reflecting the financial strength of major companies advancing biologics and targeted therapies for atopic dermatitis treatment.
Download the eBook (ToC)
Research Methodologies Used to Analyze the United States Atopic Dermatitis Market
This study employs a combination of primary and secondary research methodologies to analyze the United States Atopic Dermatitis Market. Primary research includes interviews and discussions with dermatologists, immunologists, pharmaceutical manufacturers, hospital procurement managers, healthcare providers, regulatory experts, and key industry stakeholders. Secondary research involves company annual reports, government healthcare databases, regulatory publications, industry journals, investor presentations, and market intelligence sources. Market estimations are derived using both top-down and bottom-up approaches, while data triangulation and validation techniques ensure the accuracy and reliability of market forecasts, competitive assessments, and industry trends.
Decisions Advisors Research Methodology: Trusted Insights for Strategic Decision-Making
What is Decisions Advisors Research?
Decisions Advisors research delivers comprehensive market intelligence through detailed industry analysis, competitive benchmarking, trend forecasting, and data-driven business insights. Our research methodology combines advanced analytical frameworks with extensive primary and secondary research to help organizations make informed and strategic business decisions.
Competitive Analysis:
The report offers the appropriate analysis of the key organizations/companies involved within the United States atopic dermatitis market, along with a comparative evaluation primarily based on their product of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.
Top Companies in United States Atopic Dermatitis Market
• Sanofi S.A.
• Regeneron Pharmaceuticals, Inc.
• AbbVie Inc.
• Pfizer Inc.
• Eli Lilly and Company
• Incyte Corporation
• Leo Pharma A/S
• Arcutis Biotherapeutics, Inc.
• Galderma S.A.
• Johnson & Johnson
Recent Developments:
- In September 2025, Sanofi S.A. expanded its biologic dermatology portfolio in the United States through the launch of an enhanced patient-support program for atopic dermatitis therapies, improving treatment accessibility and adherence.
- In May 2025, Regeneron Pharmaceuticals, Inc. and Sanofi S.A. announced a collaboration initiative to strengthen physician education and patient outreach efforts for advanced biologic treatments targeting moderate-to-severe atopic dermatitis.
Market Segmentation:
United States Atopic Dermatitis Market, By Drug Class
• Topical Corticosteroids
• Calcineurin Inhibitors
• PDE4 Inhibitors
• Biologics
• JAK Inhibitors
• Antihistamines
• Others
United States Atopic Dermatitis Market, By Route of Administration
• Topical
• Oral
• Injectable
United States Atopic Dermatitis Market, By Disease Severity
• Mild Atopic Dermatitis
• Moderate Atopic Dermatitis
• Severe Atopic Dermatitis
United States Atopic Dermatitis Market, By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Specialty Pharmacies
• Online Pharmacies
United States Atopic Dermatitis Market, By End User
• Hospitals
• Dermatology Clinics
• Ambulatory Care Centers
• Homecare Settings
Expert Views:
The United States Atopic Dermatitis Market is expected to witness substantial growth through 2035, supported by increasing prevalence of chronic inflammatory skin disorders, growing adoption of biologics and targeted immunotherapies, expanding healthcare expenditure, and continuous innovation in dermatology treatment solutions. Strategic product launches, collaborations, and advancements in precision medicine are anticipated to strengthen treatment outcomes and support long-term market expansion across the United States dermatology therapeutics industry.
Author: Govind and Krishna By Spherical Insights and Consulting